Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial (Q37132369)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 August 2013

Language	Label	Description	Also known as
English	Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial	scientific article published on 12 August 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Louise Provencher

15

object named as

Louise Provencher

0 references

Sandra M. Swain

object named as

Sandra M Swain

1

0 references

Eleftherios P Mamounas

19

object named as

Eleftherios P Mamounas

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Donald W Northfelt

16

object named as

Donald W Northfelt

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

author name string

Gong Tang

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Charles E Geyer

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Priya Rastogi

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

James N Atkins

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Paul P Donnellan

6

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Louis Fehrenbacher

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Catherine A Azar

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

André Robidoux

9

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Jonathan A Polikoff

10

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Adam M Brufsky

11

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

David D Biggs

12

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Edward A Levine

13

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

John L Zapas

14

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Soonmyung Paik

17

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Joseph P Costantino

18

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Norman Wolmark

20

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

0 references

publication date

12 August 2013

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

31

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

26

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

3197-3204

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3757290

14 September 2017

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3757290

14 September 2017

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3757290

14 September 2017

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3757290

14 September 2017

Gemcitabine and paclitaxel in metastatic breast cancer: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3757290

14 September 2017

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3757290

3 September 2018

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3757290

3 September 2018

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3757290

3 September 2018

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3757290

3 September 2018

Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3757290

3 September 2018

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3757290

3 September 2018

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3757290

4 December 2018

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23940225

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2012.48.1275

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37132369&oldid=2118692811"